Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma

Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33 in a deal of up to around $560m. The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan. Tolerance Bio plans Phase II clinical development of TLB-33 for thymic preservation, immune resilience. Credit: PeopleImages / Shutterstock.com. Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m. The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma…

Source: Pharmaceutical Technology